GlassScriptPhysician profile
Ashley N Stiger
NPI 1033710140
$1,336.57
in general payments reported to CMS, 2019-2025
28 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.80 · 2022: $545 · 2023: $214 · 2024: $90.46 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $228.46 | 2025 | Camzyos, Eliquis |
| Urovant Sciences INC | $211.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.17 | 2021-2024 | |
| Astellas Pharma US INC | $84.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $78.02 | 2025 | Verquvo |
| Abbvie INC. | $60.26 | 2022 | |
| Hollister Incorporated | $56.63 | 2022-2023 | Infyna Chic |
| Pfizer INC. | $47.12 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $45.63 | 2023-2024 | Aveed, Xiaflex |
| Amgen INC. | $35.80 | 2022-2025 | Repatha |
| Progenics Pharmaceuticals, INC. | $35.53 | 2023 | Pylarify |
| Dendreon Pharmaceuticals LLC | $33.71 | 2023 | Provenge |
| Davol INC. | $31.68 | 2024 | Arista Ah Flexitip |
| Abc Home Medical Supply, INC. | $30.46 | 2022-2023 | |
| Cvrx, INC. | $27.33 | 2025 | Barostim Neo System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $27.24 | 2025 | Fintepla |
| Medtronic, INC. | $27.22 | 2023 | Interstim |
| 180 Medical, INC. | $21.65 | 2022 | |
| Janssen Biotech, INC. | $20.72 | 2023 | Erleada, Akeega |
| Coloplast Corp | $20.30 | 2023 | Titan |
| Esperion Therapeutics, INC. | $19.99 | 2025 | Nexletol |
| Heartflow, INC. | $18.51 | 2025 | |
| Acerus Pharmaceuticals Corporation | $17.06 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $16.14 | 2022 | |
| Sumitomo Pharma America, INC. | $13.98 | 2024 | Gemtesa |
| Profound Medical Corp. | $13.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.09 | 2022 | |
| Allergan, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Stiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.